Impact of Isovolemic Hemodilution‐Red Cell Exchange on Health‐Related Quality of Life in Patients With Sickle Cell Disease: A Pilot Study
Journal of Clinical Apheresis · 2026
DOI: 10.1002/jca.70083 ↗At a glance
Journal article in Journal of Clinical Apheresis, 2026. Written by Alistair Murray and 4 co-authors. Institution: Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada. Major MEDLINE topics: Anemia, Sickle Cell, Quality of Life, Erythrocyte Transfusion, Hemodilution. 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Calgary Health Foundation.
Abstract (original language)
Sickle cell disease (SCD) negatively affects health‐related quality of life (HRQoL). Isovolemic hemodilution (IHD) red‐cell exchange (RCE) is being increasingly used to treat SCD‐related complications, but its impact on HRQoL has not been characterized. This single‐center pilot study assessed the effect of switching from chronic conventional RCE to IHD‐RCE on HRQoL. Adults with SCD receiving conventional RCE at the Foothills Medical Centre (Calgary, Canada) were assessed for eligibility to switch to IHD‐RCE in March–May 2023. The primary outcome was HRQoL assessed before and 6 months after switching using the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ‐Me) questionnaire. Red blood cell (RBC) utilization, RCE characteristics, clinical parameters, and complications were also assessed before and after switching to IHD‐RCE. Five patients were included. Overall, HRQoL was stable 6 months after switching from conventional RCE to IHD‐RCE, with numeric improvements from baseline in sleep, stiffness, and emotional impact subscale scores. There were modest reductions in RBC utilization per RCE session but a small increase in RCE sessions per patient, with slightly fewer days between RCE sessions. Clinical parameters were largely unchanged 6 months after switching to IHD‐RCE except for decreased ferritin levels and iron saturation and increased total iron‐binding capacity. No emergency department visits or transfusion reactions were observed during follow‐up. This pilot study suggests that SCD‐related HRQoL is maintained after switching from conventional RCE to IHD‐RCE, with potential benefits on sleep, stiffness, and emotional impact.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
- Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, Alberta, Canada.
ORCID profiles: Alistair Murray
Funding
- Calgary Health Foundation
Cite
APA
Murray, A., Sidhu, D., Rydz, N., Goodyear, D., & Uminski, K. (2026). Impact of Isovolemic Hemodilution‐Red Cell Exchange on Health‐Related Quality of Life in Patients With Sickle Cell Disease: A Pilot Study. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70083
Vancouver
Murray A, Sidhu D, Rydz N, Goodyear D, Uminski K. Impact of Isovolemic Hemodilution‐Red Cell Exchange on Health‐Related Quality of Life in Patients With Sickle Cell Disease: A Pilot Study. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70083
BibTeX
@article{Murray2026,
author = {Murray, Alistair and Sidhu, Davinder and Rydz, Natalia and Goodyear, Dawn and Uminski, Kelsey},
title = {Impact of Isovolemic Hemodilution‐Red Cell Exchange on Health‐Related Quality of Life in Patients With Sickle Cell Disease: A Pilot Study},
journal = {Journal of Clinical Apheresis},
year = {2026},
doi = {10.1002/jca.70083}
}
EUVIMED